Cell & Gene
Manufacturing CGTs: Should I Use A CDMO?
September 30, 2022
Sidley lawyers Deeona Gaskin and Raj Pai recently published an article in Cell & Gene entitled “Manufacturing CGTs: Should I Use A CDMO?” The article explains various manufacturing challenges faced by sponsors of cell and gene therapies, and considerations for companies looking to outsource manufacturing of their cell and gene therapy products to contract manufacturing organizations (CMOs) or contract development and manufacturing organizations (CDMOs).
Contacts
Related Blogs
Capabilities
Suggested News & Insights
FDA’s Elsa at Eleven Months: AI-Powered Operations and One-Day Inspections Signal a New Oversight ParadigmMay 20, 2026EU Pharma Package: Compromise Text Published – Best Efforts Required (Part 2)May 18, 2026Navigating the European Health Data Space Regulation: An (Uneasy) Marriage Between EHDS and GDPR (April 2026, Part 2)April 14, 2026Sidley Recognized in Legal 500 EMEA 2026March 25, 2026Delaware Supreme Court Makes Earnouts Less Risky For Buyers Earnout Decision Partially Reversed Because Buyer Did Not Have to Pursue an Alternative Regulatory PathwayJanuary 27, 2026EU Pharma Package: Sharp New Tools With Limited ProtectionsDecember 19, 2025
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory